Amgen’s next-generation cholesterol drug has shown it can reverse the build up of plaque build-up in coronary arteries which can lead to a heart attack or stroke. The company’s Repatha ...

Despite resilient demand, healthcare has taken a hit along with the rest of the market. This Big Pharma could boost profits ...

More than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t generate much sales momentum behind the product. Its latest gambit is ...

This stands to reason, as nearly every stage of drug development and marketing is resource- and capital-intensive, and as a ...

Ian Thompson, SVP and general manager of U.S. business operations at Amgen, shares his leadership philosophy, what he's ...

Additionally, established products like Repatha and Tezspire continue to demonstrate strong market presence. The company’s pipeline remains a key focus for investors and analysts alike.

Additionally, established products like Repatha and Tezspire continue to demonstrate strong market presence. The company’s pipeline remains a key focus for investors and analysts alike. Amgen has ...